Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Research and Markets has announced the addition of the "Advanced PET ( Positron Emission Tomography ) and SPECT ( Single Photon Emission Computed Tomography ) Global Market (2010 -2015)" report to its offerings. In a release, Research and Markets noted that report highlights include:

Propelled by the transparent reimbursement policies, new emerging economies, novel applications such as Alzheimers and continually expanding oncology application segment, the global positron emission tomography ( PET ) market is estimated to reach around $6.3 billion in 2010.

Reimbursement plays a major role in the adoption of any medical imaging technology. The approval of PET scanning reimbursement in the U.S. by the Medicare and Medicaid for the Alzheimers disease widened the opportunities for the major market participants. Currently there are approximately 4.7 million Alzheimers patients in the U.S. PET enables the radiologist to have the early diagnosis of the Alzheimer disease among the patients. Therefore, this would further increase the demand of the PET scanners among the various health care centers.

Similarly, single photon emission computed tomography scanners have been on the forefront to bring about significant changes in the diagnostic imaging equipment landscape by opening up numerous lucrative opportunities in niche market such as neuroendocrine tumor imaging. Moreover, technological advancements such as attenuation correction and image acquisition/reconstruction tools have enhanced SPECT end users' confidence in its diagnostic and prognostic capabilities. The global PET SPECT market is expected to grow from an estimated $6.5 billion in 2010 to $10.3 billion in 2015, at an estimated CAGR of 9.4 percent from 2010 to 2015. The PET segment is estimated to account for the largest share i.e. 75 percent of the overall PET SPECT installations at 3,691 units in 2010. This segment is expected to reach 6,390 units in 2015, at a CAGR of 11.6 percent for the same period.

Oncology and cardiology are the most significant applications of the PET SPECT market. Oncology accounts for about 90 percent of the PET market, whereas, cardiology accounts for about 85 percent of SPECT application market. Neurological application of PET and SPECT is a niche market and is dependent on the development of appropriate radionuclides and tracers.

Source: Research and Markets

See more about our SPECT Companies